ESMO 2023 | Novel treatment options for patients with metastatic, inoperable urothelial carcinomas

Arlene O. Siefker-Radtke, MD, MD Anderson Cancer Center, Houston, TX, discusses the novel treatment options available to patients with metastatic, inoperable urothelial carcinomas. Dr Siefker-Radtke elaborates on the addition of immunotherapies to treatment regimens, as well as their combination with other agents, to provide the best outcomes for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.